TY - JOUR
T1 - Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions
T2 - An Unaddressed and Unmet Clinical Need?
AU - Pagnesi, Matteo
AU - Regazzoli, Damiano
AU - Ancona, Marco B.
AU - Mangieri, Antonio
AU - Lanzillo, Giuseppe
AU - Giannini, Francesco
AU - Buzzatti, Nicola
AU - Prendergast, Bernard D.
AU - Kodali, Susheel
AU - Lansky, Alexandra J.
AU - Colombo, Antonio
AU - Latib, Azeem
N1 - Funding Information:
Dr. Prendergast has received research funding from Edwards Lifesciences; and speaker fees from Edwards Lifesciences, Boston Scientific, MVRx, and Symetis. Dr. Kodali has served as a consultant for Medtronic, Claret Medical, and Edwards Lifesciences; is the principal investigator of the SENTINEL trial, sponsored by Claret Medical; has served on the advisory boards of Thubrikar Aortic Valve and Dura Biotech; has received research support and travel reimbursement from Edwards Lifesciences, Claret Medical, and Medtronic; and holds equity in Thubrikar Aortic Valve (minimal) and Dura Biotech. Prof. Lansky has received research support from Keystone Heart, NeuroSave Inc., and Boston Scientific; and has received speaker/consultant fees from Keystone Heart. Dr. Latib has served on the advisory boards of Medtronic and Millipede; has received honoraria from Abbott Vascular; and has served as a consultant for Medtronic, Millipede, Valtech Cardio, MitralTech, Innovative Cardiovascular Solutions, Keystone Medical, and Mitralign. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2018 American College of Cardiology Foundation
PY - 2018/3/26
Y1 - 2018/3/26
N2 - As new transcatheter mitral valve (MV) interventions continuously evolve, potential procedure-related adverse events demand careful investigation. The risk of cerebral embolic damage is ubiquitous in any left-sided structural heart intervention (and potentially linked to long-term neurocognitive sequelae); therefore, efforts to evaluate these aspects in the field of catheter-based MV procedures are justified. Given the peculiarities of MV anatomy, MV disease, and MV procedures, the lessons learned from other transcatheter heart interventions (i.e., transcatheter aortic valve replacement) cannot be directly translated to MV applications. Through a systematic assessment of available evidence, the authors present and discuss procedure- and patient-related factors potentially associated with cerebral embolic risk during catheter-based MV interventions. Given the paucity of available data in this field, future large, dedicated studies are needed to understand whether cerebral embolic injury represents a real clinical issue during MV procedures.
AB - As new transcatheter mitral valve (MV) interventions continuously evolve, potential procedure-related adverse events demand careful investigation. The risk of cerebral embolic damage is ubiquitous in any left-sided structural heart intervention (and potentially linked to long-term neurocognitive sequelae); therefore, efforts to evaluate these aspects in the field of catheter-based MV procedures are justified. Given the peculiarities of MV anatomy, MV disease, and MV procedures, the lessons learned from other transcatheter heart interventions (i.e., transcatheter aortic valve replacement) cannot be directly translated to MV applications. Through a systematic assessment of available evidence, the authors present and discuss procedure- and patient-related factors potentially associated with cerebral embolic risk during catheter-based MV interventions. Given the paucity of available data in this field, future large, dedicated studies are needed to understand whether cerebral embolic injury represents a real clinical issue during MV procedures.
KW - cerebral embolism
KW - neurological events
KW - repair
KW - replacement
KW - transcatheter mitral valve intervention
UR - http://www.scopus.com/inward/record.url?scp=85045949644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045949644&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2017.12.018
DO - 10.1016/j.jcin.2017.12.018
M3 - Review article
C2 - 29566796
AN - SCOPUS:85045949644
VL - 11
SP - 517
EP - 528
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
SN - 1936-8798
IS - 6
ER -